<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01942447</url>
  </required_header>
  <id_info>
    <org_study_id>UKT-FMT</org_study_id>
    <secondary_id>UKT</secondary_id>
    <nct_id>NCT01942447</nct_id>
  </id_info>
  <brief_title>Fecal Microbiota Transplantation in Recurrent or Refractory Clostridium Difficile Colitis</brief_title>
  <acronym>TOCSIN</acronym>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital Tuebingen</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital Tuebingen</source>
  <brief_summary>
    <textblock>
      The host gastrointestinal microbiota is significantly influenced by antibiotic treatment
      which might favor Clostridium difficile infection (CDI), a frequent cause of community- and
      hospital-acquired, potentially life-threatening diarrhoea. CDI is followed by recurrence in
      19-35% of patients despite adequate first line antimicrobial therapy. Currently there is no
      standardized therapy of recurrent or refractory CDI, but recent studies show remarkable
      effects of fecal microbiota transplantation (FMT).

      In the current project, we aim to ideally match host and donor for FMT success in recurrent
      or refractory CDI. We will establish a clinical standard operating protocol for FMT, we will
      evaluate its safety and efficacy, and the patient acceptance and quality of life before and
      after FMT. We will analyse persistence of the donor microbiota within the recipient, define
      predictive clinical recipient and donor factors for FMT success and correlate them with
      microbial host and donor metagenomics.

      We hypothesize that our work will yield novel, individualized strategies for recurrent or
      refractory CDI. In perspective, our results may be expanded to treatment of other inflammory
      bowel diseases.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Not yet recruiting</last_known_status>
  <start_date>October 2013</start_date>
  <completion_date type="Anticipated">May 2015</completion_date>
  <primary_completion_date type="Anticipated">December 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Resolution of diarrhea</measure>
    <time_frame>2 weeks</time_frame>
    <description>Resolution of diarrhea</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Patient acceptance</measure>
    <time_frame>2 weeks</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>Persitence of FMT</measure>
    <time_frame>26 weeks</time_frame>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Clostridium Difficile</condition>
  <condition>Clostridium Difficile Infection</condition>
  <arm_group>
    <arm_group_label>FMT</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>FMT</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Standard</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Vancomycin</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>FMT</intervention_name>
    <arm_group_label>FMT</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vancomycin</intervention_name>
    <arm_group_label>Standard</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  recurrent or refractory CDI

          -  previous antimicrobial therapy includes at least on course of vancomycin 4x125 (or
             higher doses) for at least 7d

          -  CDI, defined as: 3 or more loose bowel movements/d AND (presence of C.diff. toxin in
             stools or toxin producing C. diff. strain) OR (endoscopic or histologic evidence of
             pseudomembraneous colitis)

        Exclusion Criteria:

          -  no informed consent

          -  no ability to provide informed consent

          -  immune suppression (continuous immune-suppressive drugs; steroids:
             prednisolone-equivalent &gt; 20 mg for 14d or longer)

          -  lack of appropriate donor

          -  pregnancy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Martin Goetz, Prof</last_name>
    <email>martin.goetz@med.uni-tuebingen.de</email>
  </overall_contact>
  <location>
    <facility>
      <name>Universitaetsklinikum Tuebingen</name>
      <address>
        <city>Tuebingen</city>
        <zip>72076</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Martin Goetz, Prof.</last_name>
      <email>martin.goetz@med.uni-tuebingen.de</email>
    </contact>
    <investigator>
      <last_name>Martin Goetz, Prof.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>October 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 5, 2013</study_first_submitted>
  <study_first_submitted_qc>September 13, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 16, 2013</study_first_posted>
  <last_update_submitted>October 10, 2013</last_update_submitted>
  <last_update_submitted_qc>October 10, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 11, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University Hospital Tuebingen</investigator_affiliation>
    <investigator_full_name>Martin Goetz</investigator_full_name>
    <investigator_title>Univ.-Prof. Dr. med. Martin Goetz</investigator_title>
  </responsible_party>
  <keyword>Fecal microbiota transplantation</keyword>
  <keyword>microbiota</keyword>
  <keyword>clostridium difficile</keyword>
  <keyword>clostridium difficile infection</keyword>
  <keyword>Efficacy of FMT</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vancomycin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

